<DOC>
	<DOCNO>NCT00005641</DOCNO>
	<brief_summary>RATIONALE : Bone marrow transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . Sometimes transplanted cell donor make immune response body 's normal cell . Eliminating T cell donor cell transplant may prevent happen . PURPOSE : Phase II trial study effectiveness T cell removal prevent graft-versus-host disease patient undergo bone marrow transplantation donor .</brief_summary>
	<brief_title>Removal T Cells Prevent Graft-Versus-Host Disease Patients Undergoing Bone Marrow Transplantation</brief_title>
	<detailed_description>OBJECTIVES : I . Determine incidence severity graft v host disease ( GVHD ) follow allogeneic bone marrow transplantation marrow graft modify T cell depletion counterflow centrifugal elutriation CD34+ cell selection patient high risk GVHD . II . Determine incidence graft failure follow treatment regimen patient population . III . Determine relapse rate overall survival patient population treat regimen . OUTLINE : Patients unrelated donor , mismatch related donor , match related donor diagnose acute lymphocytic leukemia , chronic lymphocytic leukemia , myeloma , advance acute myeloid leukemia ( AML ) , receive cyclophosphamide IV 60 minute day -6 -5 fractionate total body irradiation ( TBI ) 3 time day day -3 -1 , twice day 0 . Patients receive graft v host disease ( GVHD ) prophylaxis anti-thymocyte globulin ( ATG ) IV 8 hour day -2 -1 . Patients undergo allogeneic bone marrow transplantation ( ABMT ) day 0 marrow graft modify T cell depletion counterflow centrifugal elutriation CD34+ selection . Patients unable receive TBI due match mismatch related donor , age ( 56 60 ) , patient diagnose AML-CR1 , chronic myelogenous leukemia , myelodysplastic syndrome , myeloproliferative disorder match related donor , receive oral busulfan every 6 hour day -7 -4 , cyclophosphamide IV 60 minute day -3 -2 , ATG IV 8 hour day -2 -1 GVHD prophylaxis . Patients undergo T cell deplete ABMT day 0 . At pretransplantation , patient acute leukemia receive intrathecal ( IT ) methotrexate ( MTX ) follow lumbar puncture . At 48 hour follow IT MTX , patient CNS involvement receive second dose IT MTX follow oral leucovorin calcium every 6 hour 4 dos . Patients prior CNS involvement receive cranial radiotherapy 2 week . Following AMBT , patient undergo GVHD prophylaxis consist methylprednisolone IV every 12 hour day 5-22 , daily day 23-28 cyclosporine IV orally twice daily begin day -1 continue 7-9 month follow ABMT . Patients follow every 3 month death . PROJECTED ACCRUAL : Approximately 40 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy Acute myeloid leukemia ( AML ) Complete remission 1 ( CR1 ) : high risk define poor cytogenetics ( e.g. , deletion , addition , multiple abnormality ) Complete remission 2 ( CR2 ) Induction failures Relapse : least one reinduction attempt least 10 % marrow blast Acute lymphocytic leukemia CR1 : high risk define overt CNS involvement poor cytogenetics ( e.g. , addition , deletion , translocation , multiple abnormality ) CR2 Induction failures Relapse AML Chronic myelogenous leukemia Chronic phase ( CP ) 1 Accelerated phase ( AP ) /CP2 : blast phase patient require induction achievement second chronic phase prior transplantation Chronic lymphocytic leukemia Relapse : stage must receive great 3 regimen since diagnosis Multiple myeloma Primary refractory disease diagnosis Relapse ( great 2 ) : sensitive disease Plasma cell leukemia Inability achieve complete remission relapse autologous transplantation ( great 40 year ) Myelodysplasia All FAB subtypes Myeloproliferative disorder Poor response medical therapy OR Cytogenetic abnormality Severe aplastic anemia ( SAA ) ( unrelated and/or mismatch donor ) Very SAA diagnosis OR SAA : induction failures One antigen mismatch ( recipient age 15 55 ) Related donor may A , B , DR mismatch Unrelated donor may A B mismatched ( DRB1 match ) Phenotypic ( 6 6 ) match Recipient age 51 60 related donor Recipient age 41 55 unrelated donor PATIENT CHARACTERISTICS : Age : 15 60 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL SGOT/SGPT great 3 time normal PT/PTT normal Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : LVEF least 45 % MUGA scan echocardiography Greater 6 month since myocardial infarction No uncontrolled arrhythmias Pulmonary : FEV1 DCLO least 50 % predict Other : No psychosocial condition would preclude study No uncontrolled diabetes mellitus No uncontrolled thyroid disease No active serious infection HIV negative Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>